William Blair & Company’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

William Blair & Company’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-26,500	Closed	-$166K	–	1819
2018 Q3	$166K	Hold	26,500	–	–	﹤0.01%	1317
2018 Q2	$213K	Hold	26,500	–	–	﹤0.01%	1247
2018 Q1	$198K	Hold	26,500	–	–	﹤0.01%	1207
2017 Q4	$158K	Hold	26,500	–	–	﹤0.01%	1287
2017 Q3	$195K	Hold	26,500	–	–	﹤0.01%	1253
2017 Q2	$180K	Buy	26,500 +2,500	+10%	+$18.5K	﹤0.01%	1367
2017 Q1	$270K	Hold	24,000	–	–	﹤0.01%	1127
2016 Q4	$207K	Hold	24,000	–	–	﹤0.01%	1151
2016 Q3	$152K	Buy	+24,000	New	+$145K	﹤0.01%	1204
2016 Q2	–	Sell	-24,000	Closed	-$104K	–	1293
2016 Q1	$104K	Hold	24,000	–	–	﹤0.01%	1122
2015 Q4	$147K	Hold	24,000	–	–	﹤0.01%	1120
2015 Q3	$137K	Hold	24,000	–	–	﹤0.01%	1320
2015 Q2	$179K	Hold	24,000	–	–	﹤0.01%	2072
2015 Q1	$143K	Buy	24,000 +12,000	+100%	+$75.5K	﹤0.01%	2041
2014 Q4	$90K	Hold	12,000	–	–	﹤0.01%	2030
2014 Q3	$62K	Buy	+12,000	New	+$59.8K	﹤0.01%	2041

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

William Blair & Company's PGNX Position: Q4 2018 in Review

William Blair & Company sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 26,500 shares — an estimated $166K sold.

William Blair & Company first reported a position in PGNX in Q3 2014 and held it in 16 quarters. The position peaked at $270K in Q1 2017. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

William Blair & Company reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
William Blair & Company sold 26,500 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $166K.
William Blair & Company first reported a position in Progenics Pharmaceuticals Inc in Q3 2014 and held it in 16 quarters.
William Blair & Company's Progenics Pharmaceuticals Inc position peaked at $270K in Q1 2017.
150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on William Blair & Company's 13F filing for Q4 2018, filed 14 Feb 2019.